Since the increased IFNγ production during incomplete C11BM inhibition provokes PD-L1 expression in the melanoma cells, the combination of MALT1 inhibitors and anti-PD1 immune checkpoint therapy exhibits synergistic effects in the inhibition of tumor growth [105]. The gene discussed is IFNG; the disease is neoplasm.